Polar Asset Management Partners Inc. Purchases 53,100 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Polar Asset Management Partners Inc. increased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 48.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 163,000 shares of the company's stock after purchasing an additional 53,100 shares during the quarter. Polar Asset Management Partners Inc. owned approximately 0.21% of Viridian Therapeutics worth $3,708,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Great Point Partners LLC boosted its stake in shares of Viridian Therapeutics by 50.0% in the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company's stock worth $17,062,000 after buying an additional 250,000 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in Viridian Therapeutics by 62.9% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 178,855 shares of the company's stock valued at $2,327,000 after buying an additional 69,035 shares during the period. Rhumbline Advisers increased its holdings in Viridian Therapeutics by 34.5% during the second quarter. Rhumbline Advisers now owns 90,826 shares of the company's stock worth $1,182,000 after buying an additional 23,305 shares during the last quarter. Vanguard Group Inc. raised its position in Viridian Therapeutics by 7.8% in the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company's stock worth $56,632,000 after acquiring an additional 233,331 shares during the period. Finally, Candriam S.C.A. increased its stake in shares of Viridian Therapeutics by 167.8% during the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company's stock worth $9,754,000 after purchasing an additional 469,804 shares during the last quarter.

Viridian Therapeutics Trading Down 1.7 %

Shares of VRDN stock traded down $0.33 on Thursday, hitting $19.63. 1,093,430 shares of the company's stock traded hands, compared to its average volume of 1,114,035. The company's fifty day simple moving average is $22.67 and its 200 day simple moving average is $17.56. Viridian Therapeutics, Inc. has a one year low of $11.40 and a one year high of $27.20. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -4.55 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The business had revenue of $0.09 million for the quarter, compared to analysts' expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on VRDN shares. Royal Bank of Canada reiterated an "outperform" rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Thursday. HC Wainwright increased their price target on Viridian Therapeutics from $27.00 to $34.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. TD Cowen started coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating on the stock. Oppenheimer reiterated an "outperform" rating and set a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a research report on Monday, August 12th. Finally, BTIG Research boosted their price target on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, September 26th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $36.33.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the stock in a transaction dated Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the transaction, the director now directly owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. This represents a 86.68 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen F. Mahoney bought 21,400 shares of the stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the purchase, the chief executive officer now owns 21,400 shares in the company, valued at $499,262. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 1,626,400 shares of company stock worth $30,616,312. Corporate insiders own 0.65% of the company's stock.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.